3 hours OnKure Therapeutics (NASDAQ:OKUR) Earns Buy Rating from HC WainwrightMarketBeat
HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a research report on Thursday.
XHC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a research report on Thursday.
X